Eli Lilly and Company

In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Today, Lilly holds exclusive, worldwide development and commercialization rights of our JAK inhibitor, baricitinib (Olumiant^®), which was discovered by Incyte and certain back-up compounds for anti-inflammatory diseases.

Novartis International Pharmaceutical Ltd.

In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications. We retained exclusive development and commercialization rights to Jakafi^® (ruxolitinib) in the United States. Novartis also received worldwide exclusive development and commercialization rights to our c-MET inhibitor compound capmatinib and certain back-up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States.

In April 2016, Incyte and Novartis also agreed to amend their Collaboration and License Agreement, granting Novartis the rights to research, develop and commercialize ruxolitinib for GVHD outside the United States.

Agenus Inc.

In 2015, we announced a global license, development and commercialization agreement with Agenus Inc. focused on novel immuno-therapeutics using Agenus Inc.’s proprietary Retrocyte Display antibody discovery platform. The alliance is  focused on the development of checkpoint modulator antibodies directed against GITR, OX40, LAG-3, and TIM-3.

ARIAD Pharmaceuticals, Inc.

In May 2016, we entered into a Share Purchase Agreement with ARIAD Pharmaceuticals, Inc. pursuant to which we acquired ARIAD’s European subsidiaries responsible for the commercialization of Iclusig^® (ponatinib) in the European Union and 22 other countries. In addition, we entered into a License Agreement granting Incyte an exclusive license to develop and commercialize Iclusig in Europe.

Merus N.V.

In 2016, we announced a global, strategic collaboration and license agreement with Merus N.V. focused on the research, discovery and development of bispecific antibodies utilizing Merus’ proprietary Biclonics^® technology platform. The agreement grants Incyte exclusive rights for up to eleven bispecific antibody research programs, including two of Merus’ current preclinical immuno-oncology discovery programs.

Calithera Biosciences, Inc.

In 2017, we announced a global collaboration and license agreement with Calithera Biosciences, Inc. for the research, development and commercialization of CB-1158, a first-in-class, small-molecule arginase inhibitor in hematology and oncology.

MacroGenics, Inc.

In 2017, we announced an exclusive global collaboration and license agreement with MacroGenics, Inc. for MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1).

Innovent Biologics, Inc.

In 2018, we announced a strategic collaboration agreement with Innovent Biologics, Inc. for three clinical-stage product candidates discovered and developed by Incyte—pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor). Under the agreement Innovent Biologics, Inc. received the rights to develop and commercialize the three assets in hematology and oncology in Mainland China, Hong Kong, Macau and Taiwan.

Zai Lab, Ltd.

In 2019, we announced a collaboration and license agreement with Zai Lab, Ltd. for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in Greater China.